看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。9 z8 d4 o; W, p- I4 w
/ M) J4 A# d- m8 O2 V
8 o& d* W2 J! OCurrently available feasibility data for possible combination strategies. # W0 I% z3 C% r/ e! |# b
————————————————————————————————8 j0 C- `. g$ k$ \4 S) B; l
Combination Feasibility according to preliminary data / Y6 ]* V+ t+ R
——————————————————————————————————
- O) ^2 [2 ~! c9 m$ SBevacizumab + sorafenib Yes, reduced dose
- w" v+ h- Y1 s f* `- }4 `Bevacizumab + sunitinib† No + S/ }5 _' W. p% A; s
Bevacizumab + temsirolimus Yes $ h) f9 {6 O7 S
Bevacizumab + everolimus Yes 2 k L! k2 A6 O3 W2 e" ^2 c
Sorafenib + sunitinib ?
+ o4 q+ A: ^; FSorafenib + temsirolimus Yes, reduced dose . B8 l. s$ D' x/ ^- Y
Sorafenib + everolimus Yes, reduced dose
5 j. h1 f) l. c% y7 H+ d, _7 gSunitinib + temsirolimus† No ' X2 Y8 A6 y2 }% E0 U! ^
Sunitinib + everolimus ?
+ B1 g" i% w5 E! R* |Temsirolimus + everolimus ?
5 d& y0 @2 i% c }' C* ?" B" D: e' X————————————————————
: t- E y, J: h7 G' K0 y! q. g†Led to US FDA warning.6 O& u/ v6 }! s
?: As yet unattempted combination./ k1 @ q3 R2 T% h. v
|